Study of purinosome assembly in cell-based model systems with de novo purine synthesis and salvage pathway deficiencies

PLoS One. 2018 Jul 30;13(7):e0201432. doi: 10.1371/journal.pone.0201432. eCollection 2018.

Abstract

Background: The enzymes involved in de novo purine synthesis (DNPS), one of the basic processes in eukaryotic cells, transiently and reversibly form a dynamic multienzyme complex called the purinosome in the cytoplasm. The purinosome has been observed in a broad spectrum of cells, but some studies claim that it is an artefact of the constructs used for visualization or stress granules resulting from the exposure of cells to nutrient-reduced growth media. Both may be true depending on the method of observation. To clarify this point, we combined two previously used methods, transfection and immunofluorescence, to detect purinosomes in purinosome-free cells deficient in particular DNPS steps (CR-DNPS cells) and in cells deficient in the salvage pathway, which resulted in construction of the purinosome regardless of purine level (CR-HGPRT cells).

Methods and findings: To restore or disrupt purinosome formation, we transiently transfected CR-DNPS and CR-HGPRT cells with vectors encoding BFP-labelled wild-type (wt) proteins and observed the normalization of purinosome formation. The cells also ceased to accumulate the substrate(s) of the defective enzyme. The CR-DNPS cell line transfected with a DNA plasmid encoding an enzyme with zero activity served as a negative control for purinosome formation. No purinosome formation was observed in these cells regardless of the purine level in the growth medium.

Conclusion: In conclusion, both methods are useful for the detection of purinosomes in HeLa cells. Moreover, the cell-based models prepared represent a unique system for the study of purinosome assembly with deficiencies in DNPS or in the salvage pathway as well as for the study of purinosome formation under the action of DNPS inhibitors. This approach is a promising step toward the treatment of purine disorders and can also provide targets for anticancer therapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • HeLa Cells
  • Humans
  • Models, Biological*
  • Multienzyme Complexes / genetics
  • Multienzyme Complexes / metabolism*
  • Purines / biosynthesis*

Substances

  • Multienzyme Complexes
  • Purines

Grants and funding

This work was supported by the Ministry of Health of the Czech Republic [grant AZV 15-28979A, http://www.azvcr.cz, recipient MZ] and by The Charles University Grant Agency [grant GAUK 818416, recipient MK and GAUK 1102217, recipient OS, https://www.cuni.cz/UK-33.html]. Institutional support was provided by Charles University [programmes PRIMUS/17/MED/6 - recipient MZ, PROGRES Q26/LF1, UNCE 204064 - recipient VB and SVV 260367/2017 - recipients OS and MK, http://www.cuni.cz] and by the Ministry of Education, Youth and Sports of CR [LQ1604 National Sustainability Programme II, http://www.msmt.cz/].